Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Micafungin sodium
Drug ID BADD_D01456
Description Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Indications and Usage Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis. Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Marketing Status approved; investigational
ATC Code J02AX05
DrugBank ID DB01141
KEGG ID D02465
MeSH ID D000077551
PubChem ID 23666118
TTD Drug ID D06TOE
NDC Product Code 63126-908; 66529-0016; 0143-9362; 63323-728; 63323-729; 16436-0114; 65727-055; 25021-190; 71288-029; 58623-0113; 75924-308; 25021-191; 0469-3250; 71288-028; 72572-427; 66529-0005; 0469-3211; 70594-037; 69766-090; 62227-005; 53296-0114; 70594-036; 68254-0012; 0143-9361
UNII IS1UP79R56
Synonyms Micafungin | FK 463 | FK463 | FK-463 | Micafungin Sodium | Mycamine
Chemical Information
Molecular Formula C56H70N9NaO23S
CAS Registry Number 208538-73-2
SMILES CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC (=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O) C(CC(=O)N)O)C)O)O)O.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anxiety19.06.02.002--
Aspartate aminotransferase increased13.03.04.011--
Atrial fibrillation02.03.03.002--
Cardiac arrest02.03.04.001--
Coagulopathy01.01.02.001---
Delirium19.13.02.001--
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation01.01.02.002; 24.01.01.010--
Encephalopathy17.13.02.001--
Epistaxis22.04.03.001; 24.07.01.005--
Febrile neutropenia01.02.03.002; 08.05.02.004--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemorrhage intracranial17.08.01.008; 24.07.04.003--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatocellular injury09.01.07.008---
Hepatomegaly09.01.05.001---
Hyperbilirubinaemia01.06.04.003; 09.01.01.003; 14.11.01.010---
Hyperkalaemia14.05.03.001--
Hypernatraemia14.05.04.001--
Hypersensitivity10.01.03.003--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Injection site thrombosis08.02.03.028; 12.07.03.028; 24.01.01.023---
Insomnia17.15.03.002; 19.02.01.002--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
The 1th Page    1 2    Next   Last    Total 2 Pages